Overview

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Status:
Completed

Trial end date:
2018-05-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.

Phase:

Phase 3

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Chlorambucil
Lenalidomide
Thalidomide